By investing in the personalized medicine approach across cancer types and increasing PM integration scores, health systems can more rapidly implement biomarker testing-driven, high-value personalized care in routine practice, as has been attained in HER2+ mBC. The gene discussed is ERBB2; the disease is cancer.